Procedures
- Collagen Cross linking for Keratoconus and Corneal ectasias
- Fuch’s Corneal Dystrophy and Partial thickness Corneal transplants (DSAEK and DMEK)
- Pterygium surgery
- Recurrent Corneal Erosions (subsections will include PTK, Amniotic tissue transplants)
- Severe Dry Eyes and Neurotrophic keratitis
- Punctal plugs
- Autologous serum drops
- Tarsorrhaphy
- Amniotic tissue transplants
- Oxervate
Collagen Cross linking for Keratoconus and Corneal ectasias
In 2016, iLink™ corneal cross-linking became the only FDA-approved cross-linking procedure for the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® and Photrexa® Viscous eye drops, combined with ultraviolet (UV) light to stiffen and strengthen corneas weakened by keratoconus. Today, iLink™ remains the only FDA-approved corneal cross-linking procedure for progressive keratoconus, offering an effective treatment that can slow or halt the progression of this sight-threatening disease.
What is Keratoconus?
Keratoconus, often referred to as “KC,” is an eye condition in which the cornea weakens and thins over time, causing the development of a cone-like bulge and optical irregularity of the cornea. Keratoconus can result in significant visual loss and may lead to corneal transplant in severe cases.
NORMAL CORNEA
KERATOCONUS
Keratoconus Overview
Watch this video for a quick overview about keratoconus and how it can be treated.
How is progressive keratoconus treated?
Keratoconus can be treated using iLink™—the first and only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help preserve vision.
A new standard of care for progressive keratoconus
iLink™ corneal cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and Photrexa® Viscous riboflavin eye drops, combined with ultraviolet light from the KXL system to1:
• Create new corneal collagen cross-links
• Shorten and thicken collagen fibrils
• Stiffen and strengthen the cornea
At Todani Eye Associates, we are proud to offer the iLinkTM corneal cross-linking, the first and only FDA-approved treatment to slow or halt the progression of keratoconus and corneal ectasia following refractive surgery.